Skip to search formSkip to main contentSkip to account menu

apremilast

Known as: Apremilastum, Aprémilast, N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (2)

Anti-Inflammatory Agents, Non-SteroidalThalidomide

Narrower (2)

CC 10004Otezla
analogs & derivativesapremilast 28-day starter pack

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Multiple lentigines arising on resolving psoriatic plaques after treatment with apremilast
Hyperpigmented lesions confined to resolving psoriatic plaques were described initially after psoralen ultraviolet A treatment… 
Review
2018
Review
2018
Adverse events associated with apremilast use and withdrawal for psoriasis in a real‐world setting
Apremilast, a phosphodiesterase-4 inhibitor, is an oral therapy for treatment of psoriasis. Its safety profile is favorable, with… 
2018
2018
Apremilast Use in a Case of Cicatricial Ectropion Secondary to Severe Lamellar Ichthyosis.
Ichthyosis is a cutaneous disorder characterized by excessive amounts of dry thickened skin surface scales. Ocular manifestations… 
2017
2017
Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
OBJECTIVE: To examine real-world use and patient outcomes with apremilast, an oral PDE4 inhibitor, in the dermatology practice… 
2017
2017
Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.
BACKGROUND The Physician Global Assessment and Body Surface Area (PGAxBSA) composite tool is a simple, effective alternative for… 
2016
2016
Identification, characterization and HPLC quantification of impurities in apremilast
A sensitive, selective and stability indicating LC-UV method was developed for the determination of process-related impurities in… 
2016
2016
Erythrodermic Psoriasis Treated with Apremilast
Erythroderma is a rare potentially deadly exfoliative dermatitis characterized by diffuse cutaneous erythema which may be… 
Review
2015
Review
2015
Apremilast for the treatment of psoriasis
Introduction: Psoriasis is a chronic inflammatory skin disease characterized by dysregulation of the immune system and release of… 
2015
2015
Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
Psoriasis is a chronic immune-mediated inflammatory condition that affects 2-3% of the population. Apremilast was FDA-approved in… 
Highly Cited
2013
Highly Cited
2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
BACKGROUND Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works intracellularly to modulate pro… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)